Kuantum Papers Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 26, 2025, 9:03 am

Competitors of Kuantum Papers Ltd

All Competitor Stocks of Kuantum Papers Ltd

Quarterly Result

Last Updated: August 20, 2025, 7:55 am

Below is a detailed analysis of the quarterly data for Kuantum Papers Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 223.00 Cr.. The value appears to be declining and may need further review. It has decreased from 277.00 Cr. (Mar 2025) to 223.00 Cr., marking a decrease of 54.00 Cr..
• For Expenses, as of Jun 2025, the value is 183.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 217.00 Cr. (Mar 2025) to 183.00 Cr., marking a decrease of 34.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 40.00 Cr.. The value appears to be declining and may need further review. It has decreased from 60.00 Cr. (Mar 2025) to 40.00 Cr., marking a decrease of 20.00 Cr..
• For OPM %, as of Jun 2025, the value is 18.00%. The value appears to be declining and may need further review. It has decreased from 22.00% (Mar 2025) to 18.00%, marking a decrease of 4.00%.
• For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
• For Interest, as of Jun 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
• For Depreciation, as of Jun 2025, the value is 15.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 15.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 16.00 Cr.. The value appears to be declining and may need further review. It has decreased from 36.00 Cr. (Mar 2025) to 16.00 Cr., marking a decrease of 20.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be improving (decreasing) as expected. It has decreased from 28.00% (Mar 2025) to 26.00%, marking a decrease of 2.00%.
• For Net Profit, as of Jun 2025, the value is 12.00 Cr.. The value appears to be declining and may need further review. It has decreased from 26.00 Cr. (Mar 2025) to 12.00 Cr., marking a decrease of 14.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 1.38. The value appears to be declining and may need further review. It has decreased from 2.99 (Mar 2025) to 1.38, marking a decrease of 1.61.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 4:58 am

Growth

Last Updated: September 5, 2025, 9:25 am

Balance Sheet

Last Updated: August 11, 2025, 2:14 pm

Below is a detailed analysis of the balance sheet data for Kuantum Papers Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 9.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,204.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,115.00 Cr. (Mar 2024) to 1,204.00 Cr., marking an increase of 89.00 Cr..
• For Borrowings, as of Mar 2025, the value is 654.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 512.00 Cr. (Mar 2024) to 654.00 Cr., marking an increase of 142.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 246.00 Cr.. The value appears to be improving (decreasing). It has decreased from 251.00 Cr. (Mar 2024) to 246.00 Cr., marking a decrease of 5.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,113.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,888.00 Cr. (Mar 2024) to 2,113.00 Cr., marking an increase of 225.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1,619.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,475.00 Cr. (Mar 2024) to 1,619.00 Cr., marking an increase of 144.00 Cr..
• For CWIP, as of Mar 2025, the value is 156.00 Cr.. The value appears strong and on an upward trend. It has increased from 42.00 Cr. (Mar 2024) to 156.00 Cr., marking an increase of 114.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 338.00 Cr.. The value appears to be declining and may need further review. It has decreased from 371.00 Cr. (Mar 2024) to 338.00 Cr., marking a decrease of 33.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,113.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,888.00 Cr. (Mar 2024) to 2,113.00 Cr., marking an increase of 225.00 Cr..

Notably, the Reserves (1,204.00 Cr.) exceed the Borrowings (654.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Kuantum Papers Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 13.20. This value is within the healthy range. It has decreased from 21.07 (Mar 24) to 13.20, marking a decrease of 7.87.
• For Diluted EPS (Rs.), as of Mar 25, the value is 13.20. This value is within the healthy range. It has decreased from 21.07 (Mar 24) to 13.20, marking a decrease of 7.87.
• For Cash EPS (Rs.), as of Mar 25, the value is 19.39. This value is within the healthy range. It has decreased from 26.59 (Mar 24) to 19.39, marking a decrease of 7.20.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 138.97. It has increased from 128.79 (Mar 24) to 138.97, marking an increase of 10.18.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 138.97. It has increased from 128.79 (Mar 24) to 138.97, marking an increase of 10.18.
• For Dividend / Share (Rs.), as of Mar 25, the value is 3.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 3.00.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 126.86. It has decreased from 138.81 (Mar 24) to 126.86, marking a decrease of 11.95.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 28.50. This value is within the healthy range. It has decreased from 38.81 (Mar 24) to 28.50, marking a decrease of 10.31.
• For PBIT / Share (Rs.), as of Mar 25, the value is 22.31. This value is within the healthy range. It has decreased from 33.28 (Mar 24) to 22.31, marking a decrease of 10.97.
• For PBT / Share (Rs.), as of Mar 25, the value is 17.81. This value is within the healthy range. It has decreased from 28.37 (Mar 24) to 17.81, marking a decrease of 10.56.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 13.20. This value is within the healthy range. It has decreased from 21.07 (Mar 24) to 13.20, marking a decrease of 7.87.
• For PBDIT Margin (%), as of Mar 25, the value is 22.46. This value is within the healthy range. It has decreased from 27.96 (Mar 24) to 22.46, marking a decrease of 5.50.
• For PBIT Margin (%), as of Mar 25, the value is 17.58. This value is within the healthy range. It has decreased from 23.97 (Mar 24) to 17.58, marking a decrease of 6.39.
• For PBT Margin (%), as of Mar 25, the value is 14.03. This value is within the healthy range. It has decreased from 20.44 (Mar 24) to 14.03, marking a decrease of 6.41.
• For Net Profit Margin (%), as of Mar 25, the value is 10.40. This value exceeds the healthy maximum of 10. It has decreased from 15.17 (Mar 24) to 10.40, marking a decrease of 4.77.
• For Return on Networth / Equity (%), as of Mar 25, the value is 9.49. This value is below the healthy minimum of 15. It has decreased from 16.35 (Mar 24) to 9.49, marking a decrease of 6.86.
• For Return on Capital Employeed (%), as of Mar 25, the value is 10.90. This value is within the healthy range. It has decreased from 18.31 (Mar 24) to 10.90, marking a decrease of 7.41.
• For Return On Assets (%), as of Mar 25, the value is 5.45. This value is within the healthy range. It has decreased from 9.73 (Mar 24) to 5.45, marking a decrease of 4.28.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.33. This value is within the healthy range. It has increased from 0.27 (Mar 24) to 0.33, marking an increase of 0.06.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.53. This value is within the healthy range. It has increased from 0.45 (Mar 24) to 0.53, marking an increase of 0.08.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.55. It has decreased from 0.67 (Mar 24) to 0.55, marking a decrease of 0.12.
• For Current Ratio (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1.5. It has decreased from 1.02 (Mar 24) to 0.83, marking a decrease of 0.19.
• For Quick Ratio (X), as of Mar 25, the value is 0.44. This value is below the healthy minimum of 1. It has decreased from 0.64 (Mar 24) to 0.44, marking a decrease of 0.20.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.26. This value exceeds the healthy maximum of 8. It has increased from 3.55 (Mar 24) to 9.26, marking an increase of 5.71.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 22.72. This value is within the healthy range. It has increased from 14.24 (Mar 24) to 22.72, marking an increase of 8.48.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 15.47. This value is below the healthy minimum of 20. It has increased from 11.28 (Mar 24) to 15.47, marking an increase of 4.19.
• For Earning Retention Ratio (%), as of Mar 25, the value is 77.28. This value exceeds the healthy maximum of 70. It has decreased from 85.76 (Mar 24) to 77.28, marking a decrease of 8.48.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 84.53. This value exceeds the healthy maximum of 70. It has decreased from 88.72 (Mar 24) to 84.53, marking a decrease of 4.19.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 6.33. This value is within the healthy range. It has decreased from 7.90 (Mar 24) to 6.33, marking a decrease of 1.57.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.93. This value is within the healthy range. It has decreased from 5.29 (Mar 24) to 3.93, marking a decrease of 1.36.
• For Enterprise Value (Cr.), as of Mar 25, the value is 1,512.26. It has decreased from 1,786.29 (Mar 24) to 1,512.26, marking a decrease of 274.03.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.37. This value is within the healthy range. It has decreased from 1.47 (Mar 24) to 1.37, marking a decrease of 0.10.
• For EV / EBITDA (X), as of Mar 25, the value is 6.08. This value is within the healthy range. It has increased from 5.27 (Mar 24) to 6.08, marking an increase of 0.81.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.79. This value is below the healthy minimum of 1. It has decreased from 1.12 (Mar 24) to 0.79, marking a decrease of 0.33.
• For Retention Ratios (%), as of Mar 25, the value is 77.27. This value exceeds the healthy maximum of 70. It has decreased from 85.75 (Mar 24) to 77.27, marking a decrease of 8.48.
• For Price / BV (X), as of Mar 25, the value is 0.72. This value is below the healthy minimum of 1. It has decreased from 1.20 (Mar 24) to 0.72, marking a decrease of 0.48.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.79. This value is below the healthy minimum of 1. It has decreased from 1.12 (Mar 24) to 0.79, marking a decrease of 0.33.
• For EarningsYield, as of Mar 25, the value is 0.13. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.13.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness